Literature DB >> 22187396

Pediatric hemophilia: a review.

Roshni Kulkarni1, J Michael Soucie.   

Abstract

The hemophilias are the most common X-linked inherited bleeding disorders, which if not properly managed can lead to chronic disease and lifelong disabilities. The challenges and issues in newborns are different from that in older children and adults. Bleeding events still predominate as the diagnostic trigger in children, however, the sites of bleeding vary with age. While delivery-associated intracranial hemorrhage (ICH), circumcision, and venipuncture bleeding are common in the newborn period, joint disease and head trauma occur in the older child and adolescent. Awareness of clinical manifestations and treatment complications are crucial in instituting appropriate management and implementing preventive strategies. Currently, inhibitors and ICH are the most challenging complications and prophylaxis is emerging as the optimal preventive care strategy. © Thieme Medical Publishers.

Entities:  

Mesh:

Year:  2011        PMID: 22187396     DOI: 10.1055/s-0031-1297164

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  8 in total

1.  Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.

Authors:  Randolph B Lyde; Hyun Sook Ahn; Karen K Vo; Danuta J Jarocha; John Tkaczynski; Elsa Treffeisen; Spencer K Sullivan; Rodney M Camire; Denise E Sabatino; Deborah L French; Mortimer Poncz
Journal:  Blood Adv       Date:  2019-05-14

2.  Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection System.

Authors:  R Kulkarni; R J Presley; J M Lusher; A D Shapiro; J C Gill; M Manco-Johnson; M A Koerper; T C Abshire; D DiMichele; W K Hoots; P Mathew; D J Nugent; S Geraghty; B L Evatt; J M Soucie
Journal:  Haemophilia       Date:  2016-11-04       Impact factor: 4.287

3.  Diagnostic evaluation of our patients with hemophilia A: 17-year experience.

Authors:  Kamuran Karaman; Sinan Akbayram; Mesut Garipardıç; Ahmet Fayik Öner
Journal:  Turk Pediatri Ars       Date:  2015-06-01

4.  Recombinant Factor VIII Measurement in a Hemophilia A Patient Undergoing Cardiopulmonary Bypass-Supported Cardiac Surgery.

Authors:  Jennifer Bezaire; Dorothy Thomson; Erick McNair
Journal:  J Extra Corpor Technol       Date:  2018-09

5.  Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.

Authors:  Shin Young Hyun; Seon Yang Park; Soon Yong Lee; Hoon Kook; Sang Hoon Paik; In-Jin Jang; Kun Soo Lee
Journal:  Yonsei Med J       Date:  2015-07       Impact factor: 2.759

Review 6.  Clinical and laboratory approaches to hemophilia a.

Authors:  Hassan Mansouritorghabeh
Journal:  Iran J Med Sci       Date:  2015-05

Review 7.  Consensus review of the treatment of cardiovascular disease in people with hemophilia A and B.

Authors:  Victor A Ferraris; Leonard I Boral; Alice J Cohen; Susan S Smyth; Gilbert C White
Journal:  Cardiol Rev       Date:  2015 Mar-Apr       Impact factor: 2.644

8.  Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation.

Authors:  Patricia E Zerra; Connie M Arthur; Satheesh Chonat; Cheryl L Maier; Amanda Mener; Sooncheon Shin; Jerry William L Allen; W Hunter Baldwin; Courtney Cox; Hans Verkerke; Ryan P Jajosky; Christopher A Tormey; Shannon L Meeks; Sean R Stowell
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.